腹腔热灌注化疗治疗结直肠癌腹膜癌  

Intraoperative peritoneal hyperthermic chemotherapy for treatment of peritoneal carcinomatosis from colorectal cancer

作　　者：杨肖军（综述）[1] 杨国樑（审校）[1] 李雁（审校）[1] 

机构地区：[1]武汉大学中南医院肿瘤科武汉大学肿瘤防治研究中心,430071

出　　处：《国际肿瘤学杂志》2007年第5期384-386,共3页Journal of International Oncology

摘　　要：结直肠癌局域性进展可形成腹膜癌，大约10％的患者初诊即发现腹膜癌，有4％～19％的患者在根治术后随访期发生腹膜癌，25％～35％的复发患者以腹膜癌为唯一表现。全身化疗对此类腹膜癌只是姑息性治疗，中位生存期不足6个月。缩瘤术加腹腔热灌注化疗则可清除宏观和微观癌细胞。荷兰癌症中心的Ⅰ、Ⅱ、Ⅲ期临床试验总结分析表明，接受完全缩瘤术加腹腔热灌注化疗者的中位生存期可达42．9个月，1、3、5年生存率分别是95％、56％和43％，明显高于传统治疗方法，已成为英国、法国、意大利、荷兰、西班牙和澳大利亚等国的标准治疗。Loeal- regional progression of colorectal cancer can result in peritoneal carcinomatosis, which is usually found in about 10% of the patients at primary diagnosis ,4%- 19% of patients during follow up after curative resection of colorectal cancer,25%-35% of patients with recurrence. Systemic chemotherapy is only palliative for such peritoneal carcinomatosis, with median survival of less than 6 months. In contrast, cytoreductire surgery plus intraoperative peritoneal hyperthermic chemotherapy （ IPHC ） can achieve total eradication of both macroscopic and microscopic tumor burden. Long term survival analysis of the phases Ⅰ , Ⅱ and Ⅲ clinical trials by Netherlands Cancer Institute reveals a median survival time of up to 42. 9 months, and 1- ,3-, and 5-year survival rates of 95% ,56% and 43% for patients with complete cytoreduction plus IPHC. The median survival time and survival rates are significantly higher than those with conventional therapy. This new treatment has been accepted as the standard therapy in United Kingdom, France, Italy, the Netherlands, Spain and Australia.

关 键 词：结直肠肿瘤 腹膜肿瘤 高温 诱发 灌注 局部 

分 类 号：R730.5[医药卫生—肿瘤] R735.3[医药卫生—临床医学]